Elicio Therapeutics Reports $39.6M Net Loss, Cash Runway Only Into Q3 2026
Summary
Elicio Therapeutics reported a net loss of $39.6 million and an EPS of $(2.58) for the year ended December 31, 2025, as detailed in its 10-K filing. Critically, the company stated its cash runway is expected to last only into Q3 2026. This financial update provides the specific figures underpinning the company's financial position, following its universal shelf registration (S-3) for up to $400 million filed on February 27, 2026. The significant net loss and short cash runway are highly material for a clinical-stage biotech, indicating a high likelihood of near-term dilution through an equity offering or the need for partnerships to extend operations. Investors will be closely watching for announcements regarding a specific financing event or strategic partnerships to address the cash runway and fund ongoing clinical development, particularly for its ELI-002 program.
At the time of this announcement, ELTX was trading at $10.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $190.6M. The 52-week trading range was $4.60 to $14.93. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.